Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease
- PMID: 30796007
- PMCID: PMC6682416
- DOI: 10.1016/j.parkreldis.2019.02.017
Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease
Abstract
Mobility deficits, including gait disturbance, balance impairments and falls, are common features of Parkinson's disease (PD) that negatively impact quality of life. Mobility deficits respond poorly to dopaminergic medications, indicating a role for additional neurotransmitters. Due to the critical role of cortical input to gait and balance, acetylcholine-an essential neurotransmitter system for attention-has become an area of interest for mobility. This review aimed to identify the role of cholinergic function on gait, balance, and falls in PD using three techniques; pharmacological, imaging, and electrophysiological. Studies supported the role of the cholinergic system for mobility in PD, with the most promising evidence indicating a role in falls. Imaging studies demonstrated involvement of anterior cholinergic (basal forebrain) systems in gait, and posterior (brainstem) systems in balance. However, this review identified a small number of studies which used varying protocols, making comparisons difficult. Further studies are warranted, measuring comprehensive gait and balance characteristics as well as gold standard falls detection to further quantify the relationship between ACh and mobility in PD.
Keywords: Acetylcholine; Balance; Falls; Gait; Parkinson's disease.
Copyright © 2019. Published by Elsevier Ltd.
Conflict of interest statement
Conflicts of Interest
FH has a significant financial interest in APDM, a company that may have a commercial interest in the results of this research and technology- this potential institutional and individual conflict has been reviewed and managed by OHSU
Figures




Similar articles
-
Effect of augmenting cholinergic function on gait and balance.BMC Neurol. 2015 Dec 23;15:264. doi: 10.1186/s12883-015-0523-x. BMC Neurol. 2015. PMID: 26697847 Free PMC article. Clinical Trial.
-
Normal and pathological gait: what we learn from Parkinson's disease.J Neurol Neurosurg Psychiatry. 2012 Oct;83(10):979-85. doi: 10.1136/jnnp-2012-302263. Epub 2012 Jun 29. J Neurol Neurosurg Psychiatry. 2012. PMID: 22752693 Free PMC article. Review.
-
Topography of Cholinergic Nerve Terminal Vulnerability and Balance Self-Efficacy in Parkinson's Disease.J Integr Neurosci. 2024 Sep 24;23(9):178. doi: 10.31083/j.jin2309178. J Integr Neurosci. 2024. PMID: 39344233 Free PMC article.
-
Balance and gait disorders in de novo Parkinson's disease: support for early rehabilitation.J Neurol. 2024 Dec 12;272(1):11. doi: 10.1007/s00415-024-12804-4. J Neurol. 2024. PMID: 39666175 Free PMC article.
-
Gait characteristics and falls in Parkinson's disease: A systematic review and meta-analysis.Parkinsonism Relat Disord. 2018 Dec;57:1-8. doi: 10.1016/j.parkreldis.2018.07.008. Epub 2018 Jul 17. Parkinsonism Relat Disord. 2018. PMID: 30041848
Cited by
-
Molecular mechanisms underlying the neuroprotection of environmental enrichment in Parkinson's disease.Neural Regen Res. 2023 Jul;18(7):1450-1456. doi: 10.4103/1673-5374.360264. Neural Regen Res. 2023. PMID: 36571341 Free PMC article. Review.
-
Cholinergic nucleus degeneration and its association with gait impairment in Parkinson's disease.J Neuroeng Rehabil. 2024 Jul 18;21(1):120. doi: 10.1186/s12984-024-01417-7. J Neuroeng Rehabil. 2024. PMID: 39026279 Free PMC article.
-
Role of the Central Cholinergic Nervous System in Motor and Non-Motor Symptoms of Parkinson's Disease.Curr Neuropharmacol. 2025;23(10):1232-1248. doi: 10.2174/011570159X368923250313045859. Curr Neuropharmacol. 2025. PMID: 40108903 Review.
-
Cholinesterase inhibitors for gait, balance, and fall in Parkinson disease: a meta-analysis.NPJ Parkinsons Dis. 2021 Nov 25;7(1):103. doi: 10.1038/s41531-021-00251-1. NPJ Parkinsons Dis. 2021. PMID: 34824258 Free PMC article.
-
Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design.Mov Disord. 2023 Oct;38(10):1774-1785. doi: 10.1002/mds.29519. Epub 2023 Jun 26. Mov Disord. 2023. PMID: 37363815 Free PMC article.
References
-
- Muslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ, Determinants of disability and quality of life in mild to moderate Parkinson disease, Neurology 70(23) (2008) 2241–7. - PubMed
-
- Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M, Caregiver-burden in parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability, Parkinsonism Relat Disord 12(1) (2006) 35–41. - PubMed
-
- Fasano A, Appel-Cresswell S, Jog M, Zurowkski M, Duff-Canning S, Cohn M, Picillo M, Honey CR, Panisset M, Munhoz RP, Medical Management of Parkinson’s Disease after Initiation of Deep Brain Stimulation, Canadian Journal of Neurological Sciences 43(5) (2016) 626–34. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical